ANI Pharmaceuticals, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 1 | $0.97 | $1.02 | $1.00 |
| Q2 2024 | 1 | $0.93 | $0.97 | $0.95 |
| Q3 2024 | 1 | $1.08 | $1.09 | $1.09 |
| Q4 2024 | 2 | $1.35 | $1.52 | $1.45 |
| Q1 2025 | 2 | $1.00 | $1.21 | $1.11 |
| Q2 2025 | 1 | $1.29 | $1.35 | $1.32 |
| Q3 2025 | 1 | $1.38 | $1.45 | $1.41 |
| Q4 2025 | 1 | $1.51 | $1.58 | $1.54 |
ANI Pharmaceuticals, Inc. Earnings Date And Information
ANI Pharmaceuticals, Inc. last posted its earnings results on Friday, November 8th, 2024. The company reported $1.34 earnings per share for the quarter, topping analysts' consensus estimates of $1.09 by $0.25. The company had revenue of 148.33 M for the quarter and had revenue of 486.82 M for the year. ANI Pharmaceuticals, Inc. has generated $1 earnings per share over the last year ($0.94 diluted earnings per share) and currently has a price-to-earnings ratio of -155.73. ANI Pharmaceuticals, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, February 27th, 2025 based on prior year's report dates.
ANI Pharmaceuticals, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 11/08/2024 | Q3 2024 | $1.09 | -$1.27 | -2.36 | $144.37 M | $148.33 M |
| 08/06/2024 | Q2 2024 | $0.93 | -$0.12 | -1.05 | $129.09 M | $138.04 M |
| 05/10/2024 | Q1 2024 | $0.98 | $0.84 | -0.14 | $137.43 M | |
| 02/29/2024 | Q4 2023 | $0.80 | $0.04 | -0.76 | $131.65 M | |
| 11/08/2023 | Q3 2023 | $0.76 | $0.50 | -0.26 | $111.92 M | $131.83 M |
| 08/09/2023 | Q2 2023 | $0.64 | $0.33 | -0.31 | $99.87 M | $116.55 M |
| 05/08/2023 | Q1 2023 | $0.34 | $0.06 | -0.28 | $106.79 M | |
| 03/09/2023 | Q4 2022 | $0.68 | -$0.26 | -0.94 | $94.23 M | |
| 11/09/2022 | Q3 2022 | $0.58 | -$0.53 | -1.11 | $78.36 M | $83.82 M |
| 08/08/2022 | Q2 2022 | $0.12 | -$0.92 | -1.04 | $71.97 M | $73.86 M |
| 05/10/2022 | Q1 2022 | $0.08 | -$1.25 | -1.33 | $64.48 M | |
| 03/15/2022 | Q4 2021 | -$1.70 | $60.93 M | |||
| 11/01/2021 | Q3 2021 | $0.71 | -$0.37 | -1.08 | $49.70 M | $52.06 M |
| 08/06/2021 | Q2 2021 | $0.65 | -$1.17 | -1.82 | $46.40 M | $48.63 M |
| 05/07/2021 | Q1 2021 | $0.73 | $0.01 | -0.72 | $54.52 M | |
| 03/11/2021 | Q4 2020 | -$0.30 | $57.25 M | |||
| 11/05/2020 | Q3 2020 | $0.92 | $0.04 | -0.88 | $51.50 M | $52.98 M |
| 08/06/2020 | Q2 2020 | $0.71 | -$1.03 | -1.74 | $46.93 M | $48.47 M |
| 05/07/2020 | Q1 2020 | $0.89 | -$0.59 | -1.48 | $49.77 M | |
| 02/27/2020 | Q4 2019 | $1.18 | -$0.41 | -1.59 | $47.97 M |
ANI Pharmaceuticals, Inc. Earnings: Frequently Asked Questions
-
When is ANI Pharmaceuticals, Inc.'s earnings date?
ANI Pharmaceuticals, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, February 27th, 2025 based off last year's report dates.
-
Did ANI Pharmaceuticals, Inc. beat their earnings estimates last quarter?
In the previous quarter, ANI Pharmaceuticals, Inc. (:ANIP) reported $1.34 earnings per share (EPS) to beat the analysts' consensus estimate of $1.09 by $0.25.
-
How can I listen to ANI Pharmaceuticals, Inc.'s earnings conference call?
The conference call for ANI Pharmaceuticals, Inc.'s latest earnings report can be listened to online.
-
How can I read ANI Pharmaceuticals, Inc.'s conference call transcript?
The conference call transcript for ANI Pharmaceuticals, Inc.'s latest earnings report can be read online.
-
How much revenue does ANI Pharmaceuticals, Inc. generate each year?
ANI Pharmaceuticals, Inc. (:ANIP) has a recorded annual revenue of $486.82 M.
-
How much profit does ANI Pharmaceuticals, Inc. generate each year?
ANI Pharmaceuticals, Inc. (:ANIP) has a recorded net income of $486.82 M. ANI Pharmaceuticals, Inc. has generated $0.95 earnings per share over the last four quarters.
-
What is ANI Pharmaceuticals, Inc.'s price-to-earnings ratio?
ANI Pharmaceuticals, Inc. (:ANIP) has a price-to-earnings ratio of -155.73 and price/earnings-to-growth ratio is 1.12.
